Novel targets and strategies to combat borreliosis.

Novel targets and strategies to combat borreliosis. Appl Microbiol Biotechnol. 2020 Jan 17;: Authors: Strnad M, Grubhoffer L, Rego ROM Abstract Lyme borreliosis is a bacterial infection that can be spread to humans by infected ticks and may severely affect many organs and tissues. Nearly four decades have elapsed since the discovery of the disease agent called Borrelia burgdorferi. Although there is a plethora of knowledge on the infectious agent and thousands of scientific publications, an effective way on how to combat and prevent Lyme borreliosis has not been found yet. There is no vaccine for humans available, and only one active vaccine program in clinical development is currently running. A spirited search for possible disease interventions is of high public interest as surveillance data indicates that the number of cases of Lyme borreliosis is steadily increasing in Europe and North America. This review provides a condensed digest of the history of vaccine development up to new promising vaccine candidates and strategies that are targeted against Lyme borreliosis, including elements of the tick vector, the reservoir hosts, and the Borrelia pathogen itself. PMID: 31953560 [PubMed - as supplied by publisher]
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Tags: Appl Microbiol Biotechnol Source Type: research

Related Links:

Could wildfires be depleting the ozone all over again? Staff Writer Paul Voosen talks with host Sarah Crespi about the evidence from the Polarstern research ship for wildfire smoke lofting itself high into the stratosphere, and how it can affect the ozone layer once it gets there. Next, we talk ticks—the ones that bite, take blood, and can leave you with a nasty infection. Andaleeb Sajid, a staff scientist at the National Cancer Institute, joins Sarah to talk about her Science Translational Medicine paper describing an mRNA vaccine intended to reduce the length of tick bites to before the pests can transmit diseases...
Source: Science Magazine Podcast - Category: Science Authors: Source Type: podcasts
Immunobiology. 2021 Jul 13;226(5):152091. doi: 10.1016/j.imbio.2021.152091. Online ahead of print.ABSTRACTThe spike protein of coronavirus is key target for drug development and other pharmacological interventions. In current study, we performed an integrative approach to predict antigenic sites in SARS-CoV-2 spike receptor binding domain and found nine potential antigenic sites. The predicted antigenic sites were then assessed for possible molecular similarity with other known antigens in different organisms. Out of nine sites, seven sites showed molecular similarity with 54 antigenic determinants found in twelve pathogen...
Source: Immunobiology - Category: Allergy & Immunology Authors: Source Type: research
At my animal hospital in upstate New York, an epicenter of the U.S. tick epidemic, my dog Fawn lets out a whimper as the veterinarian injects her with her annual Lyme disease shot. I roll my eyes. She doesn’t know how good she has it. The injection means that if a tick bites her (and in rural New York, a tick always does), the creepy crawly will feast on dog blood that’s been supercharged with a Lyme bacteria-killing substance, and Lyme disease won’t be transmitted to Fawn. I wish I could be shot up with that superpower. Currently, there is no human vaccine for Lyme disease—even though more than two...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Disease feature Source Type: news
Disrupting transmission of Borrelia burgdorferi sensu lato complex (B. burgdorferi) from infected ticks to humans is one strategy to prevent the significant morbidity from Lyme disease. We have previously shown that an anti-OspA human mAb, 2217, prevents transmission of B. burgdorferi from infected ticks in animal models. Maintenance of a protective plasma concentration of a human mAb for tick season presents a significant challenge for a preexposure prophylaxis strategy. Here, we describe the optimization of mAb 2217 by amino acid substitutions (2217LS: M428L and N434S) in the Fc domain. The LS mutation led to a 2-fold in...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Vaccine. 2021 Mar 31:S0264-410X(21)00363-7. doi: 10.1016/j.vaccine.2021.03.059. Online ahead of print.ABSTRACTCurrently there is no human vaccine against Lyme borreliosis, and most research focuses on recombinant protein vaccines, as such a vaccine has been proven to be successful in the past. The expression of recombinant antigens in meningococcal Outer Membrane Vesicles (OMVs), with the OMV functioning both as adjuvant and delivery vehicle, greatly enhances their potential. Immunization studies in mice have shown that OMV-based vaccines can protect against various pathogens and an OMV-based meningococcal vaccine is appro...
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
Lyme disease (LD) caused by Borrelia burgdorferi is the most prevalent tick-borne disease. There is evidence that vaccines based on tick proteins that promote tick transmission of B. burgdorferi could prevent LD.
Source: BMC Genomics - Category: Genetics & Stem Cells Authors: Tags: Research article Source Type: research
ConclusionA DNA tattoo vaccine against OspC induced high specific IgG titers and provided near total protection against B. burgdorferi ss infection by tick challenge. In contrast, DNA tattoo vaccines against tick proteins TSLPI, Salp15, tHRF, and Tix-5 induced low to moderate IgG titers and did not provide protection. Therefore, DNA tattoo vaccination does not seem a suitable vaccine strategy to identify, or screen for, tick antigens for anti-tick vaccines. However, DNA tattoo vaccination is a straightforward and effective vaccination platform to assess novel B. burgdorferi sl antigen candidates in a relevant tick challenge model.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Lyme disease is a tick-borne infection caused by the bacteria Borrelia burgdorferi. Current diagnosis of early Lyme disease relies heavily on clinical criteria, including the presence of an erythema migrans rash. The sensitivity of current gold-standard diagnostic tests relies upon antibody formation, which is typically delayed and thus of limited utility in early infection. We conducted a study of blood and skin biopsy specimens from 57 patients with a clinical diagnosis of erythema migrans. Samples collected at the time of diagnosis were analyzed using an ultrasensitive, PCR-based assay employing an isothermal amplificat...
Source: Journal of Clinical Microbiology - Category: Microbiology Authors: Tags: Bacteriology Source Type: research
Abstract Lyme disease (LD) is an emerging zoonotic infection that is increasing in incidence in North America, Europe, and Asia. With the development of safe and efficacious vaccines, LD can potentially be prevented. Vaccination offers a cost-effective and safe approach for decreasing the risk of infection. While LD vaccines have been widely used in veterinary medicine, they are not available as a preventive tool for humans. Central to the development of effective vaccines is an understanding of the enzootic cycle of LD, differential gene expression of Borrelia burgdorferi in response to environmental variables, a...
Source: Current Issues in Molecular Biology - Category: Molecular Biology Authors: Tags: Curr Issues Mol Biol Source Type: research
(Virginia Tech) Renowned tick immunobiologist Utpal Pal wants to adapt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Biotechnology | Borrelia | Lyme Disease | Microbiology | Vaccines